Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores

Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores

Background: Both tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are known to reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This study aimed to compare the difference in HCC risk reduction between TDF and ETV in treatment-naïve patients with CH...

Full description

Bibliographic Details
Main Authors: Yan Huang, Lichang Chen, Rui Huang, Chuanwu Zhu, Jia Shang, Yunsong Qian, Jianqi Lian, Longgen Liu, Jianning Jiang, Chenghai Liu, Honglian Gui, Qing Xie
Format: Article
Language:English
Published: SAGE Publishing 2022-06-01
Series:Therapeutic Advances in Chronic Disease
Online Access:https://doi.org/10.1177/20406223221102791

Internet

https://doi.org/10.1177/20406223221102791

Similar Items